{"entries":[{"caption":"Pembrolizumab Reactions by Organ System","key":"tbl-pembrolizumab","order":{"number":6,"section":[4,3,0,0,0,0,0]}},{"caption":"Bar chart of outcome of immune checkpoint inhibitors","key":"fig-result","order":{"number":2,"section":[4,2,0,0,0,0,0]}},{"caption":"Descriptive Statistics","key":"tbl-summarytable","order":{"number":1,"section":[4,1,0,0,0,0,0]}},{"caption":"Avelumab Reactions by Organ System","key":"tbl-avelumab","order":{"number":4,"section":[4,3,0,0,0,0,0]}},{"caption":"Random Forest Evaluation Metrics","key":"tbl-randomforest","order":{"number":7,"section":[4,3,0,0,0,0,0]}},{"caption":"Nivolumab Reactions by Organ System","key":"tbl-nivolumab","order":{"number":5,"section":[4,3,0,0,0,0,0]}},{"caption":"Study Flowchart","key":"fig-processing1","order":{"number":1,"section":[3,2,0,0,0,0,0]}},{"caption":"Reactions by Organ System and Drug","key":"tbl-summarytable1","order":{"number":2,"section":[4,2,0,0,0,0,0]}},{"caption":"Bar chart of types of reactions","key":"fig-result1","order":{"number":3,"section":[4,2,0,0,0,0,0]}},{"caption":"Atezolizumab Reactions by Organ System","key":"tbl-atezolizumab","order":{"number":3,"section":[4,3,0,0,0,0,0]}}],"headings":["summaryabstract","introduction","general-background-information","description-of-data-and-data-source","questionshypotheses-to-be-addressed","methods","data-aquisition","data-import-and-cleaning","statistical-analysis","results","exploratorydescriptive-analysis","basic-statistical-analysis","full-analysis","discussion","summary-and-interpretation","strengths-and-limitations","conclusions","references"]}